Rhizen’s cancer drug Umbralisib gets USFDA nod: Alembic Pharma – The Economic Times Alembic Pharma on Tuesday said its associate company Rhizen Pharmaceuticals AG’s product Umbralisib, which was licensed to TG Therapeutics, has received approval from the US health regulator the drug for the treatment of certain forms of cancer. In a regulatory filing, Alembic […]
Read More
Alembic’s affiliate Rhizen bags US regulator nod for oral cancer drug In what could further boost Alembic Pharmaceutical’s oncology business, its co-owned clinical-stage biopharmaceutical firm Rhizen Pharmaceuticals AG has bagged US Food and Drug Administration (USFDA) nod for an oral drug indicated in treating lymphoma. Umbralisib is indicated for treatment of adult patients with relapsed […]
Read More
Two-year-old girl, diagnosed with a rare type of cancer, gets successfully treated in Chennai hospital CHENNAI: Doctors at the Gleneagles Global Health City in Chennai successfully treated a 2-year-old from Assam, who was detected with a lesion in her mouth last year in April. According to a statement from the hospital, even though the lesion […]
Read More